> All the big AIM fraud exposés
> 300 articles and podcasts a month
> Hot share tips
> Original investigations by our experienced team
> No ads, no click-bait, no auto-play videos
By HotStockRockets | Wednesday 13 June 2018
Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
We are getting increasingly used to Premaitha (NIPT) announcing more and more large non-UK distribution agreements. And fear not there will be much more on that front in the weeks and months that lie ahead. It will be a hot summer for Premaitha and for we loyal shareholders. But, for now, there is something a bit different.
The company has signed an agreement with Coastal Genomics, a biotechnology engineering firm based in Vancouver, Canada, to develop advanced technologies for clinical DNA sequencing tests. Coastal will work to enhance Premaitha’s, already market-leading, product giving it an even clearer technological edge which, we would hope, would add to the sales momentum.
It has been an awfully long time since we first tipped these shares and it has been a bumpy ride - for which we apologise. But now the company is profitable, generating cash and with a high margin enjoying a real top and bottom line ramp up. That is reflected in how the shares have rallied to 8.5p-8.8p.
The original tip was at 17p with a limit buy price of 19p although we did move that higher before the Illumina "episode". Our new Limit buy price is 12p, the target is 25p to sell and we expect to be there by Christmas. This really is one to average down on at this level. STRONG BUY.
Never miss a story.
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Comments are turned off for this article.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen